Temasek Holdings
http://www.temasekholdings.com.sg/Temasek Holdings is an Asian investment firm headquartered in Singapore. Its portfolio spans various industries including telecommunications & media, financial services, real estate, transportation & logistics, energy & resources, infrastructure, engineering & technology as well as bioscience & healthcare. As of March 2007, the net value of its portfolio is more than US$100 billion, concentrated principally in Singapore, Asia and the OECD economies. Temasek's total shareholder return since its inception in 1974 has been more than 18% compounded annually. It has a corporate credit rating of AAA/Aaa by rating agencies Standard & Poor's and Moody's respectively.
In December of 2007, Temasek Holdings invested $4.4 billion in Merrill Lynch (NYSE: MER) common stock.
View Older Stories View More Recent Stories
-
D3 Bio Launches with US$200 Million Investment to Develop Precision Medicines Addressing Unmet Patient Needs in Oncology & Immunology
-
Roth CH Acquisition I (ROCH) to Combine With PureCycle Technologies
-
Roth CH Acquisition I to Combine With PureCycle Technologies, Accelerating a Revolution in Plastics Recycling Through Impact Investing
-
Techstars Launches the Sustainability Challenge
-
Roth CH Acquisition I to Combine With PureCycle Technologies, Accelerating a Revolution in Plastics Recycling Through Impact Investing
-
ChickP Launches Non-GMO Chickpea Starch
-
Form 13F-NT Temasek Capital (Private For: Sep 30
-
Form 13F-HR Temasek Holdings (Privat For: Sep 30
-
Form 13F-NT Temasek Life Sciences For: Sep 30
-
Form SC 13G SQZ Biotechnologies Co Filed by: Temasek Holdings (Private) Ltd
-
BioNTech Announces Third Quarter 2020 Financial Results and Corporate Progress
-
BioNTech Announces Third Quarter 2020 Financial Results and Corporate Progress
-
Southeast Asia's internet economy to cross $100 billion this year: industry report
-
Form 4 SQZ Biotechnologies Co For: Nov 03 Filed by: Temasek Holdings (Private) Ltd
-
Blaize Names NSITEXE Authorized Sales Representative in Japan
-
IDC giant GDS secondary listing receives great support led by its promising prospect
-
Form 3 SQZ Biotechnologies Co For: Oct 29 Filed by: Temasek Holdings (Private) Ltd
-
Vertex Ventures HC Announces the Addition of George Golumbeski, PhD and Faheem Hasnain as Executive Advisors
-
Gracell Biotechnologies Raises $100 Million in Series C Funding to Advance Next Generation CAR-T Cell Therapies
-
Apeel Adds $30M In New Funding to Help Smallholder Farmers Join The Global Food System
-
Alvotech Announces Private Placement Financing
-
WebMD Health Corp. to Acquire coliquio
-
Investors line up for Ant Group's record $34.4 billion IPO
-
ImpossibleTM Burger Debuts in Canadian Grocery Stores, Accelerating Retail and International Growth
-
Trip.com Group CEO Jane Sun named in Fortune’s “Most Powerful Women International” 2020 list
-
Trip.com Group CEO Jane Sun named in Fortune’s “Most Powerful Women International” 2020 list
-
Yuanfudao Raises US$2.2 Billion in New Financing, Valuing the Company at US$15.5 Billion, Becoming the Most Valued Ed-Tech Company Worldwide
-
Chinese online tutoring start-up Yuanfudao raises $2.2 billion, values firm at $15.5 billion
-
Business Leaders Seeking to Step Up their Sustainability Leadership Now Have a Roadmap
-
Disney's Bob Iger invests in animal-free dairy startup Perfect Day
-
Perfect Day Appoints Robert Iger To Board Of Directors
-
Exclusive: Ferragamo family explores stake sale as stars' shoemaker seeks to recover shine - sources
-
Impossible Foods Is Doubling Its R&D Team and Seeking World’s Best Scientists to Help Eliminate Animal Agriculture
-
Impossible Foods Accelerates International Growth as Flagship Product Debuts in Asian Grocery Stores
-
SOUTHEAST ASIA’S LARGEST PRIVATE HEALTHCARE PROVIDER PARKWAY PANTAI INSTALLS AUTOMATED LAB SYSTEM FOR DIRECT MULTIPLEX RT-PCR COVID-19 TEST
-
China's Ant wins Hong Kong nod for $35 billion dual listing: sources
-
Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited Announce an Exclusive Licensing Agreement to Develop and Commercialize Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in
-
Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited Announce an Exclusive Licensing Agreement to Develop and Commercialize Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in
-
CBC-incubated Everest Medicines Successfully Lists on HKEX
-
Singapore's Temasek establishes new asset manager overseeing $55 billion
-
Exclusive: Malaysia Airlines group low on cash, big discounts from lessors sought
-
Investors at CNBC conference anticipate more market volatility but see opportunities
-
Amundi expands in China as Beijing further opens up asset management
-
WebMD Health Corp. to Offer New Digital Tools to Help Consumers Manage Their Health
-
NUVIA Raises $240M Series B Funding as it Accelerates Plans to Deliver Industry Leading CPU Performance to the Data Center
-
NUVIA Raises $240M Series B Funding as it Accelerates Plans to Deliver Industry Leading CPU Performance to the Data Center
-
Bowery Farming Announces Availability in 650 Stores, Marking 600% Growth This Year
-
WeWork sells control of China unit; says unit got $200 million in funding
-
Slutty Vegan Founder Pinky Cole and Music Mogul Jermaine Dupri Join Impossible Foods in a Nationwide Voter Registration Drive
-
Impossible Foods Quickly Expands to Canada’s Favorite Restaurant Chains

